Objectives: Liquorpheresis (CSF ®ltration) has been shown to be of bene®t in various neurologic disorders, including sporadic ALS. Liquorpheresis in patients with familial ALS, has not been investigated so far. Methods: A 52-year-old woman with familial ALS is reported who underwent liquorpheresis during 4 consecutive days. During this period, 875 ml CSF were ®ltered o via an intrathecal catheter and a combined mechanical and ionic ®lter by means of a bi-directional syringe pump. Results: Immediately after treatment and 2 weeks later there was subjective, but no objective, improvement of her symptoms, assessed by the Norris score and measurements of the elbow extension, vital capacity, F-waves of both ulnar nerves and automatic EMG of the right brachial biceps and anterior tibial muscles. Conclusion: Liquorpheresis does not seem to be helpful in the treatment of familial ALS.
Introduction
Liquorpheresis (cerebrospinal¯uid (CSF) ®ltration) has been shown to be of bene®t in various neurologic disorders, including sporadic amyotrophic lateral sclerosis (ALS). 1 ± 3 The therapeutic eect in these disorders is said to be due to the removal of toxic metabolites, cells, in¯ammatory mediators or antibodies. 2, 3 In familial ALS, which accounts for up to 10% of all ALS patients, liquorpheresis has not been applied so far.
Case report
We report the data of a 52-year-old woman, with a three-and-a-half-year history of slowly progressive weakness of the lower limbs. After clinical, laboratory, electrophysiological and imagery examinations, the diagnosis of probable ALS was established according to the E1 Escorial criteria. 4 Since both her mother and sister had died from ALS at the age of 51 and 48 years respectively, familial ALS was assumed. Both daughters of the patient, 28 and 32 years old, were clinically unaected. Screening of all ®ve SOD-1 gene exons for mutations, using a polymerase chain reaction (PCR) single-stranded conformational polymorphism (SSCP), failed to detect any abnormal patterns on two separate occasions in all three women. The negative result does not exclude familial ALS, because only 20 ± 30% of the families have SOD-1 mutations. 5 At presentation, the patient was able to walk unaided but with frequent pauses and occasional falls on an even¯oor. She could not climb stairs and after falls she was unable to get up without support. She had been on riluzole, 100 mg/day, for 1 year. On neurologic examination, the jaw jerk was hyperactive but tongue and speech were unaected. In the upper limbs, muscle strength was normal but skilled left hand movements were disturbed. Deep tendon re¯exes were hyperactive and the small hand muscles were atrophic bilaterally. No fasciculations or sensory disturbances could be observed. Concerning the lower extremities, paraparesis (MRC grade 4) and wasting with distal accentuation and absent deep tendon re¯exes were found. The plantar response was extensor on the left and mute on the right side. Fasciculations could be observed in both anterior tibial muscles.
Liquorpheresis was carried out via an intrathecal 18G catheter and a bi-directional syringe pump (Flofors 1 , Infors AG, Bottmingen, Switzerland) and a mechanical/ionic ®lter (CSF-1during exercise. Subjectively, transfers became safer and fatigability during exercise decreased. Four days after the last ®ltration she fell but could get up from the¯oor by herself. Fourteen days after therapy she had regained the ability to climb a maximum of 20 stairs with pulling. Three weeks after the last ®ltration, the subjective improvement had vanished. To objectively assess the therapeutic eect of liquorpheresis, the Norris score was applied and measurements of vital capacity and elbow extension force (by means of a hand-held dynamometer), F-wave examinations of the left and right ulnar nerves and peak-ratio EMG interference pattern analysis 6 of the right brachial biceps and anterior tibial muscles were carried out before and 1, 7 and 14 days after ®nishing therapy. The results of these investigations showed liquorpheresis to be of little help (Table 1) . Except for headache at the beginning of the ®rst two ®ltrations and occasional paraesthesias in both legs, the course of the therapy was uneventful. CSF examination after the last ®ltration revealed only mild pleocytosis (62/3, normal: 712/3) and a discrete increase of protein (64 mg%, normal: 15 ± 45 mg%).
Discussion
Contrary to previous reports, liquorpheresis led to a subjective but not objective improvement of motor abilities in the presented patient with familial ALS.
1,2
The reported subjective improvement was interpreted as being due to a placebo eect. Arguments for a placebo eect are the rapidity of the improvement and the fact that it lasted only for 2 weeks. All applied tests failed to con®rm the subjective bene®t. The slight increase of the Norris score immediately after therapy was within the intertest variability as well as thē uctuations of the force measurements, the F-wave results and those of the automatic EMG. Whether electromyography is capable of documenting a possible bene®t only a few days after therapy, remains doubtful.
No reliable data concerning this question are available so far. The improvement of the vital capacity after the ®rst week could be attributed to a learning eect.
The dierent therapeutic eect of liquorpheresis in sporadic and familial ALS could be explained by the dierent pathogenic background of sporadic and familial ALS. In sporadic ALS, factors like AMPA/ kainate, C4d, superoxide radicals, microglia antibodies, glutamate, sodium-channel blocking agents or unknown toxins are suspected to play a pathogenic role, but it is unclear if these factors are responsible for the development of familial ALS as well. 7 ± 9 Furthermore, it is unknown if removal of these pathogenic factors by liquorpheresis is possible and if it is responsible for the reported therapeutic bene®t. Only the possibility that these factors or other unknown blocking CSF components could be responsible for the development of familial ALS and the lack of any other eective therapy, justi®ed the application of liquorpheresis in the presented patient.
Limitations of the study were that only a single patient was investigated, that the data were uncontrolled and that there was no prior hypothesis as to how big a change could be expected.
Though liquorpheresis is easily applicable and without major side eects, it does not seem to be eective in patients with familial ALS. 
